The US Food and Drug Administration (FDA) has accepted Biogen Idec's biologics license application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. Using the company's ...
Tags: FDA, Idec BLA, hemophilia B
Biogen Idec and Elan are seeking approvals from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for first-line use of Tysabri (natalizumab) in anti-JCV antibody negative patients with multiple sclerosis (MS). ...
Harvard researchers have been able to use sequencing technology to store 70 billion copies of a yet-unpublished book in DNA binary code. The results of the project by researchers at Harvard University's Wyss Institute for Biologically ...
Tags: Harvard, sequencing technology, DNA binary code, 70 billion books
The Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS). The product monograph change will help enable ...
Tags: label change, Health Canada, risk assessment
Biogen Idec (BIIB) and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement, pursuant to which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic ...
Tags: Steinert Disease, antisense drug